NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,727−0.03%VIX25.64−9.01%latest tape · as of 18:05 UTC
The Screen · Healthcare · Medical Care Facilities
Universal Health Services
UHS · a US exchange · USD · Market cap $10.4B · 101,500 employees
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.66, read 2026-11-05
Ethical passes the values gate
Price195.50 USD
Fair value237.51
Ethical score83.1/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup176.05+11.0% to today ✓Accumulation gives way to Markup first Markup read since August
2026-09-15Read Accumulation172.72+13.2% to today ✓Markup gives way to Accumulation
2026-08-15Read Markup169.72+15.2% to today ✓Distribution gives way to Markup after a 17% rise in 6 weeks
2026-07-02Read Distribution145.17+34.7% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Universal Health Services holds its Markup at $195.50. Consolidating, no directional conviction, held for 52 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 52 days
Price at the screen
$195.50
Valuation
7.22 trailing · 7.38 forward price to earnings
Values screen
PASS· score 83.1
Beta
1.11
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.27%
Below 33%
Interest-bearing debt is just 33.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.65%
Below 49%
Money owed to the company is 17.6% of assets, under the 49% limit.
Pass
Revenue purity
0.01%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Universal Health Services clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UHS's ethical verdict changes
Today UHS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly an 18% discount to our $237.51 fair value, narrow competitive moat, 5.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 17.7% discount to the base estimate.
Where our models see it going: fair-value estimate $237.51, with a range of $210.77 to $351.28, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
US hospitals priced like a broken business
Walk into any busy US emergency room and the operator behind the scenes is often grinding through thin margins to keep beds full. Universal Health Services runs acute care hospitals and behavioural facilities across the country, yet the shares sit at a forward multiple of just 6 times earnings with revenue climbing 10 percent and return on equity at 21 percent.
That valuation gap to our fair value of 255 dollars looks wide for a business that passes every ethical check and carries a narrow moat. Seventeen analysts already lean buy with a median target of 204 dollars, but the market still prices in far more trouble than the cash generation suggests.
The catch is reimbursement pressure and labour costs that can swing quickly in healthcare, plus the narrow moat leaves room for local competitors to chip away. Even strong returns can fade if policy shifts hit harder than expected.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UHS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$176.05-4.9%Entry 16
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $192.
2026-10-27Accumulation$185.10+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$185.10+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$185.10+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$185.10+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$185.10+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$185.10+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$185.10+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$185.10+4.4%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $196. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Accumulation$177.35+0.9%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $195.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
